1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6F857182390A92D3C0025869A0041FB8E
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/F857182390A92D3C0025869A0041FB8E?OpenDocument
18
19OpenDocument
2018.97.9.175
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Product Launch » Influences on Market Entry

Document Excerpt: Disease Awareness Program Excellence: Utilizing Advocacy Groups and Social Media

DB Image

Excerpt in Cart

ID: MD-772


Features:

8 Info Graphics

20 Data Graphics

440+ Metrics

6 Narratives


Pages/Slides: 4


Published: 2021


Delivery Format: Online PDF Document


 

License Options:


Download FREE Excerpt

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
To download this excerpt, click "Download Free Excerpt".

To return to the study abstract to purchase the full study -
click here

This excerpt includes research findings and metrics from document #5672 “Disease Awareness Program Excellence: Utilizing Advocacy Groups and Social Media”.

Industries Profiled:
Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Biopharmaceutical; Public Relations; Chemical; Health Care; Communications; Clinical Research; Laboratories


Companies Profiled:
AbbVie; Adamas Pharmaceuticals; AstraZeneca; Bayer; Biogen; Catalyst Pharmaceuticals; CSL Behring; Daiichi Sankyo; Eli Lilly and Company; EMD Serono; FleishmanHillard; Fresenius Medical Care; Genentech; Genzyme; Indivior; Merck KGaA; Merck Sharp & Dohme; Myovant Sciences; Nevakar; NexGen Healthcare; Novartis; Prometheus Laboratories; PruGen Pharmaceuticals; Sanofi; Teva Pharmaceutical Industries Ltd; Tokai Pharmaceuticals; Vertex Pharmaceuticals; ZS Pharma

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.